Muthu Meyyappan

Providing strategic guidance to a VC-backed, AI-driven digital health startup, focusing on pre-commercial launch activities, including market positioning, go-to-market strategy, and stakeholder engagement to drive adoption in personalized healthcare.

Transformed Menarini’s U.S. Oncology business from an IVD kit and instrument supplier into a full CLIA/CAP-certified laboratory services organization expanding the company’s footprint from hardware-driven sales to recurring, high-margin testing revenue. Built the commercial engine from the ground up, assembling and leading a multidisciplinary team across sales, marketing, MSLs, and product management, growing from 0 to 8 territories within 12 months. Partnered closely with global R&D, market access and regulatory teams to align product development and market readiness strategies. Launched MenariniSearch® cfDNA/RNA pan-cancer genomic profiling test (blood and CSF), positioning Menarini as a key innovator in the U.S. liquid biopsy and MRD market. Drove adoption of the FDA-cleared CellSearch® CTC assay for solid tumors (breast, prostate, colorectal, brain) and hematologic malignancies (multiple myeloma). Achieved 300% growth in test orders within 18 months and exceeded annual P&L targets while improving gross margins through optimized pricing and payer alignment strategies. Revitalized the pharma services division, expanding custom biomarker and companion diagnostic programs supporting pre-clinical drug discovery through Phase I–IV clinical trials. Built strategic partnerships with CROs, biopharma, and translational research teams, aligning assay development with investigational endpoints and regulatory requirements. Delivered 106% to budget while strengthening Menarini’s position as a trusted diagnostics partner in clinical development and precision medicine.

Accountable for global commercial and customer support functions driving growth across Congenica’s CE-IVD NGS SaaS platform, clinical interpretation services, and pharma insights business spanning inherited disease and oncology. Key member of the Executive Management team shaping strategic product direction, contributing to Series C fundraising ($50M), and crafting a business plan to position the company for investor exit within 3–5 years. Built and scaled global teams across AMER, EMEA, and APAC, establishing partnerships with national genome programs (Korea Genome Project, Hong Kong Genome Project, Singapore Genome Program) and expanding SaaS adoption in clinical and research settings. Led pharma and CRO engagement, delivering insights to support biomarker discovery, pre-clinical development, and precision medicine clinical trials, while establishing enterprise partnerships in oncology and rare disease. Introduced SaaS industry best practices, improved customer success operations, and leveraged KOL networks to drive adoption, resulting in measurable increases in NGS sample volume and expanded global market share.

Built and led Variantyx’s U.S. commercial and genetic counseling organization from the ground up, scaling from zero to twelve territories within a year. Recruited and developed high-performing regional teams that drove rapid adoption of Genomic Unity® whole-genome and exome sequencing (WGS/WES) tests across neurology, oncology, cardiology, and endocrinology. Achieved 140% year-over-year growth in test volumes, establishing Variantyx as a leading innovator in rare disease and hereditary cancer genomics. Forged strategic partnerships with leading molecular diagnostic labs, including a 7-year agreement with Quest Diagnostics for assay validation, white-labeled reporting, and clinical interpretation services. Designed and implemented billing and reimbursement strategies, securing coverage from commercial payers and Medicare ensuring sustainable revenue growth. Leveraged the proprietary Genomic Intelligence® software platform to streamline NGS data analysis and interpretation, aligning product strategy with translational research.

Led a worldwide commercial and customer excellence organization responsible for $46M+ in annual revenue for QIAGEN's Bioinformatics franchise focusing on Discovery and Clinical solutions. Established cross-selling strategies between business units spanning Life Sciences, Molecular Diagnostics and Bioinformatics covering a whole spectrum of NGS workflow solutions from consumables, instruments to data interpretation software. Led a specialized business team responsible for the Personalized Healthcare business and for the commercial launch of QIAGEN's first NGS instrument - the GeneReader system coupled with powerful clinical decision support software. Achieved 5% revenue growth for the business area in 2016 versus 2015.

Established a new Center of Excellence for Advanced Genomics consisting of a team of Inside Sales professionals to support the field sales force globally. Led the creation, execution and monitoring of high impact sales engagement programs with Medical Affairs to support QIAGEN's new "Sample to Insight"​ workflow selling approach. Represented the "voice of sales" by partnering with Product Development and Marketing in lead generation campaigns targeting discovery and clinical customers. Member of the senior leadership team that provided strategic guidance for the post-merger integration of BIOBASE with QIAGEN.

Managed a $10 million P&L for the North American division, identifying and implementing cost-saving measures that contributed to an improvement in profitability. Managed all aspects of bioinformatics software and database licensing from contract negotiation to closure in North America, Europe, Asia Pacific and Japan. Member of the executive management team responsible for increasing the shareholder value that resulted in the successful sale of BIOBASE GmbH to QIAGEN.

Reported to the CEO, led a team of sales, marketing and field applications scientists via regional offices in Germany, USA, India and Japan that doubled company revenue over 6 years. Managed customer relationships with key commercial accounts such as Eli Lilly, Merck and Sanofi-Aventis and government institutions such as the NIH. Expertise in communicating value proposition of rare genetic variant databases and software for geneticist, genetic counselors, clinicians and computational biologists.

Managed a team of sales managers and field applications scientists in the US as well as distributors in Japan to meet regional revenue expectations.

Provided technical account management and global scientific support for >35 pharmaceutical and biotech customers in the US, Europe and Asia. Managed and streamlined distributor activities, including sales and support, in Japan and Korea.